Table 1.
Samples from BC experiment. Subtype indicates the molecular characterization of the breast cancer based on the presence of HER2, PR and ER markers in the tumor cells (Dai et al., 2015).
| Patient | Subtype | Tissue | Total Cells |
|---|---|---|---|
| BC01 | luminalA | Breast | 22 |
| BC02 | luminalA | Breast | 53 |
| BC03 | luminalB | Breast | 33 |
| BC04 | HER2 | Breast | 55 |
| BC05 | HER2 | Breast | 76 |
| BC06 | HER2 | Breast | 18 |
| BC07 | TNBC | Breast | 50 |
| BC08 | TNBC | Breast | 22 |
| BC09 | TNBC | Breast | 55 |
| BC10 | TNBC | Breast | 15 |
| BC11 | TNBC | Breast | 11 |
| BC03 | luminalB | Lymphnode | 53 |
| BC07 | TNBC | Lymphnode | 52 |
HER2: ER-, PR-, HER2+ tumour cells.
LuminalA: ER+ and/or PR+, HER2- tumour cells.
LuminalB: ER+ and/or PR+, HER2+ tumour cells.
TNBC: ER- PR- and HER2-.